Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Recovery -1% Improvement Relative Risk c19early.org/cp Baksh et al. NCT04373460 CSSC-004 Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 1,070 patients in the USA (June 2020 - October 2021) No significant difference in recovery Baksh et al., The J. Infectious Diseases, doi:10.1093/infdis/jiad023 Favors conv. plasma Favors control
Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial
Baksh et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad023, CSSC-004, NCT04373460 (history)
Baksh et al., Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a.., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad023, CSSC-004, NCT04373460
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 1,070 outpatients in the USA, showing no significant difference in recovery with convalescent plasma treatment.
risk of no recovery, 1.0% higher, RR 1.01, p = 0.62, treatment 381 of 538 (70.8%), control 381 of 532 (71.6%), NNT 125, inverted to make RR<1 favor treatment, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Baksh et al., 31 Jan 2023, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 26 authors, study period 3 June, 2020 - 1 October, 2021, average treatment delay 6.0 days, trial NCT04373460 (history) (CSSC-004).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit